الفهرس 
Physiology of prostate
Materials and methodsOnly 14 pages are availabe for public view
 |  | from | 112 |  |  |
| | | from | 112 | | |
Abstract
- 84-
SUMMARY
A group of 57 patient with bladder outflow obstruction due to
B.P.H. were treated in 3 comparative study with finQstride(Proscar, M.K.
906), 5 - a- reductase inhibitor,S mg I day or prazocin 0.5 mg. twice daily
starting by small dose and increasing it graduallyto lmg/day or placebo
for 12 weeks.
Subsequently 18 patients received finastride 5 mg I 24 hrs and 17
patient received .prazorcin 0.5 mg twice daily and 15 patient received
placebo.
~* In the treated patients, P.S.A. level decline significantlywith finastride
group only.
* Total symptom score and peak flow rate and the amount of residual urine
decrease significantly with finastride & prazosin group only but
•
placebo showed no significant improvement in these parameters
Maximum flow rate increase by rates of 2 mll see in finastride group
and about 1.5 mll sec. with prazosin after 12 weeks treatment.
* Significant reduction in size of the prostate occurs only with finastride
group. It decreased by about 30 gm after 12 weeks treatment with
standard deviation 14.35.
* With prazocin and placebo, no significant reduction of prostate size
occurred.
* After 12 week of drug free period, the size of the gland start to increase
and the symptom score start to increase but by very small degrees (non
significant).
* The same occurred with prazoeine, due to release of inhibitory effect on
a - adrenoceptors.
T-
85-
- This means that after stoppage of finastride therapy, the
dilydrotestosterone level start to increase again and the gland start to
increase in size with recurrence of symptoms.
- So finastride shows some efficacy in treatment of BPH, with minimal
toxicity but long periods may be necessary to achieve maximal effect.